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Abstract
Background: Strokes are a leading cause of morbidity and the first cause of adult disability in the
United States. Currently, no biomarkers are being used clinically to diagnose acute ischemic stroke.
A diagnostic test using a blood sample from a patient would potentially be beneficial in treating the
disease.
Results: A classification approach is described for differentiating between proteomic samples of
stroke patients and controls, and a second novel predictive model is developed for predicting the
severity of stroke as measured by the National Institutes of Health Stroke Scale (NIHSS). The
models were constructed by applying the Logical Analysis of Data (LAD) methodology to the mass
peak profiles of 48 stroke patients and 32 controls. The classification model was shown to have an
accuracy of 75% when tested on an independent validation set of 35 stroke patients and 25
controls, while the predictive model exhibited superior performance when compared to
alternative algorithms. In spite of their high accuracy, both models are extremely simple and were
developed using a common set consisting of only 3 peaks.
Conclusion: We have successfully identified 3 biomarkers that can detect ischemic stroke with an
accuracy of 75%. The performance of the classification model on the validation set and on cross-
validation does not deteriorate significantly when compared to that on the training set, indicating
the robustness of the model. As in the case of the LAD classification model, the results of the
predictive model validate the function constructed on our support-set for approximating the
severity scores of stroke patients. The correlation and root mean absolute error of the LAD
predictive model are consistently superior to those of the other algorithms used (Support vector
machines, C4.5 decision trees, Logistic regression and Multilayer perceptron).
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Background
Strokes are the third leading cause of morbidity in the
United States, affecting nearly 700,000 Americans annu-
ally. Two major types of stroke, ischemic stroke (due to
blood clotting) and hemorrhagic stroke (due to bleeding
inside the brain), require opposite treatments. An early
and rapid diagnosis of strokes is critical for proper treat-
ment of the patients. CT scan and MRI are the effective
imaging modalities for diagnosis of strokes; however,
such expensive tools are available only in specialized hos-
pitals. The objective of this study is to discover biomarkers
of ischemic stroke which could potentially be used for
diagnosis of ischemic stroke. Once the potential biomark-
ers are discovered, their amino-sequences can be identi-
fied and be used to develop clinical assays in the next
phase of the study. Current study is focused on biomarker
discovery on ischemic stroke without any comparison
with hemorrhagic stroke.
Mass spectrometry is emerging as a key tool for high
throughput characterization of peak profiles for clinical
serum or plasma samples. The combination of mass spec-
trometry and bioinformatics has been proven to be an
effective means for the discovery of potential multiple
biomarkers for various cancers, such as ovarian [1,2],
breast [3], and prostate [4] cancers, and other diseases
from patient's serum or plasma samples [5,6]. SELDI (Sur-
face-Enhanced Laser Desorption/Ionization) is widely
used to acquire the peak profiles from 2 kDa to 200 kDa
for a large number of clinical samples. Other high resolu-
tion mass spectrometer, such as prOTOF 2000 (Perk-
inElmer, MA), also has shown promise in the discovery of
potential biomarkers for Alzheimer's disease [6]. In this
study, we used high throughput SELDI techniques to
screen 48 stroke patients and 32 healthy controls in order
to discover novel biomarkers for the diagnosis of ischemic
stroke. The samples were fractionated with Ciphergen's
serum fractionation kit with anion exchange resin in 96-
well format into 6 fractions. The peak profiles for 5 frac-
tionated samples were acquired with Ciphergen Protein-
Chip Reader PBSIIc using IMAC and CM10 biochips. The
mass spectra were analyzed with CiphergenExpress3.0 to
generate peak maps. Then the Logical Analysis of Data
(LAD) methodology was applied to build a classification
model for distinguishing the stroke patients from con-
trols. To validate the model, a validation dataset of SELDI
data were acquired in the same way as the training dataset
from an independent set of 35 stroke patients and 25
healthy controls.
LAD is a data mining method based on combinatorics,
Boolean functions, and optimization [7-9] that has been
successfully applied to data analysis problems in different
domains, including biology and medicine [10-14]. The
novelty of the approach presented in this paper is that we
use robust pre-processing steps and the LAD methodology
to mine proteomic data to discover a minimum sized sup-
port-set. A remarkable feature of LAD is its ability to dis-
cover not only potential biomarkers but also potential
combinatorial biomarkers.
In this study, we restrict our analyses to ischemic stroke.
From here on we refer to an ischemic stroke patient sim-
ply as a stroke patient.
Methods and Results
The main aim of this study is to identify a small set of
peaks to develop LAD models for the purpose of (i) clas-
sifying an individual observation as a stroke patient or as
a control, and (ii) predicting the severity score of a stroke
patient. In this section, firstly we describe the data. Next,
we discuss the pre-processing steps that we applied on this
proteomic dataset. Then we introduce the main concepts
of Logical Analysis of Data and illustrate them in the con-
text of our analysis of the SELDI data consisting of peak
profiles of 48 stroke patients (referred to as "positive"
observations) and 32 controls (referred to as "negative"
observations). Each stroke patient or control is described
as a vector of numerical components, with each value cor-
responding to a peak in the SELDI MS (mass spectrum). In
what follows, we refer to stroke patients and controls sim-
ply as observations, and we use the terms peak and varia-
ble interchangeably.
2.1. Description of the samples and SELDI MS data
Two sets of plasma samples were collected from stroke
patients and healthy adult volunteers according to the
IRB-approved (Institutional Review Board) protocol. The
blood samples of stroke patients were collected in a local
hospital (Suburban Hospital, Bethesda, USA). Follow-up
samples in 3 and 6 months after stroke were also collected
for future studies. Those stroke patients with cardiovascu-
lar instability, severe anaemia, hemorrhagic diathesis, cur-
rent infection or current severe allergic disorders were
excluded from the study. Blood samples for healthy con-
trol patients were collected in the NIH blood bank (NIH,
Bethesda, USA). Healthy volunteers with active medical
problems (allergies, allergic disorders or current sympto-
matic infection) were also excluded from the study. Table
1 shows the distribution of the clinical data (age, gender
and sampling time). The values in this table are median ±
standard deviation if the variable is numerical, and pro-
portion if the variable is binary.
The samples were fractionated into 6 fractions with
Ciphergen's serum fractionation kit and SELDI mass spec-
tra were acquired for fractions 1, 3, 4, 5 and 6 with Cipher-
gen's ProteinChip PBSIIc Reader using CM10 and IMAC
chips according to the protocols provided by the manu-
facturer. Same fractionated samples were applied to CM10BMC Medical Informatics and Decision Making 2008, 8:30 http://www.biomedcentral.com/1472-6947/8/30
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and IMAC chips. Each sample was run in duplicate. Each
ProteinChip was acquired with two laser settings. Quality
controls with 12 pooled samples that were run together
with clinical samples indicated that the %CV (Percent
coefficient of variation) of the reproducibility was within
20–30% for major 20–30 peaks.
2.2. Pre-processing
The SELDI MS data collected for this study contained
many peaks, each of which potentially corresponds to the
intensity level of a specific protein. In fact, many of these
peaks are irrelevant for the recognition of a stroke patient
(as opposed to a control). In this subsection, we describe
the procedure used for retaining only those peaks which
display good properties in terms of shape, reproducibility,
and relevance to the problem of distinguishing between
stroke patients and controls.
Out of the peaks originally identified by the SELDI mass
spectrometer, we initially selected a subset using the peak
detection algorithm in CiphergenExpress 3.0. The criteria
for selecting peaks are as follows:
Low M/Z focus: S/N = 2.5, valley = 2.0, 10%
spectra as 1st pass
S/N = 1.5, valley = 1.5,
0.3% mass window as 2nd pass
High M/Z focus: S/N = 2.5, valley = 2.5,
10% spectra as 1st pass
S/N = 2.0, valley = 2.0,
0.3% mass window as 2nd pass
The choice of peak detection thresholds is based on oper-
ator's experience to balance the peak number and signal/
noise. The peak detection thresholds were set for training
set and kept same for validation set. Using the above cri-
teria for selecting peaks, a total of 1,495 SELDI MS peaks
were retained. All retained SELDI MS peak intensities were
normalized. The standard normalization formula for the
value xij of a variable xi in an observation j is xij= mi + σi  ,
where mi is the mean of xi, and σi is its standard deviation,
and   is the normalized value. In the course of the LAD
analysis, we observed that some peaks selected by the
peak detection algorithm were either very noisy or poorly
defined. The inclusion of such peaks in the LAD model
could degrade its significance, as rules derived from noisy
data cannot be considered reliable.
This set of 1,495 peaks was further simplified to retain a
subset of peaks based on the following filters:
1. Reproducibility: The SELDI technique used to screen 48
stroke patients and 32 healthy controls was repeated twice
using two different bioprocessors. Duplication error –
which is defined as the proportion of deviation of the
measurement from the average – is calculated for each
observed value. The peaks which have an absolute dupli-
cation error exceeding 30% in more than 30% of the
observations are considered to have low reproducibility
and are eliminated;
2. Predictive power: High quality combinatorial patterns
with characteristics: degree 2, homogeneity of at least 80%
and prevalence of at least 80% (see section 2.4 for defini-
tion of pattern characteristics) were generated and the
peaks participating in these were retained;
3. Quality of spectrum: Each of the peaks that were
retained was manually examined in terms of peak shape
(whether peaks are significantly pronounced and distinct
from each other).
After the application of this filtering procedure, we
obtained a subset of 96 well-defined, relevant peaks. The
flow chart in Figure 1 depicts the above pre-processing
steps.
2.3. Discretization and Feature Selection
A standard step in the analysis of data containing numer-
ical variables with LAD is the procedure of discretization,
in which each numerical variable is assigned a (usually
′ xij
′ xij
Table 1: The distribution of clinical data
Training Validation
Stroke patients Controls Stroke patients Controls
Number of subject 48 32 35 25
Age 78 ± 13.59 76 ± 7.71 74.5 ± 14.00 75 ± 7.29
Gender (male) 52% 34% 45% 44%
Sampling in 48 hr* 65% N/A 100% N/A
* The blood sample was collected after the strokeBMC Medical Informatics and Decision Making 2008, 8:30 http://www.biomedcentral.com/1472-6947/8/30
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small) number of cut-points, or threshold levels, that rep-
resent activity/intensity levels of that variable. A simple
interpretation of such a cut-point is that of establishing a
threshold value under which a variable is considered to be
"low" and above which the variable is considered to be
"high." As we shall see later, cut-points are the basis for
the synthesis of general rules that can be used for classifi-
cation and prediction purposes.
For each peak, we have determined one or more relevant
cut-points. Virtually any intensity value of a peak can be
considered a cut-point. However, we focus on identifying
cut-points with a high distinguishing power. For example,
-0.15 is such a critical value for peak C043564_: the set of
observations for which C043564_ takes a value larger
than -0.15 includes 28 of 32 controls, while the set of
observations for which C043564_ takes a value less than -
0.15 includes 37 out of 48 patients.
We shall associate to a peak p and cut-point c an "indicator
variable" I(p > c) defined to take the value 1 on those
observations for which the intensity of p is greater than c,
Flowchart for the pre-processing procedure Figure 1
Flowchart for the pre-processing procedure.
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and to take the value 0 on those observations for which
the intensity of p is less than or equal to c. For example, if
p is the peak C043564_ and -0.15 is a cut-point of p, then
the corresponding indicator variable I(C043564_ > -0.15)
is equal to 1 for the observations for which C043564_
exceeds -0.15, and 0 for the other observations.
A feature selection procedure is applied during the discre-
tization process and only a small subset of indicator vari-
ables are retained by solving a set-covering model [8]. The
set of peaks corresponding to the selected indicator varia-
bles is called a "support-set." We selected 5 indicator var-
iables, corresponding to a support-set of 3 peaks,
presented in Table 2.
The three peaks used in this model are C08689_4,
C043564_, and C044761_. Because of the differences
observed in the M/Z values of the peaks measured in the
training and validation sets, we show in Table 2 the sup-
port-set used in the training set, along with the corre-
sponding matching peaks used in the validation set. Note
that the M/Z values obtained in the validation set are not
the same as those in the training set, but are still quite
close. The M/Z value and the shape of the peak were used
as criteria to match them. Indeed, C043560_ in Table 2
(observed in IMAC chip in fraction 6) is the same peak as
C043564_ (observed in IMAC chip in fraction 6).
The SELDI MS for these three peaks are shown in Figure 2.
Figures 2a and 2b show the typical peak of C08689_4 in
the training and validation datasets. Figures 2c and 2d
show the typical peaks of C043564_ and C044761_ in the
training and validation datasets.
In some datasets, indicator variables alone can separate
positive observations from the negative ones. This is not
the case in the dataset considered in this study, and for
this reason, we consider the use of combinations of indi-
cator variables, as described in the next subsection.
2.4. Combinatorial patterns
Below we show how one or more indicator variables can
be used in order to produce rules that can define sub-
groups of interest within the data. While an indicator var-
iable can partially predict the outcome by relating the
high or low value of a variable with a specific outcome,
the simultaneous use of more than one indicator variable
allows for the definition of more complex rules that can
be used for the precise classification of an observation.
Such rules are called "combinatorial patterns" and can be
regarded to be indicative of a specific condition.
Combinations of indicator variables can define homoge-
neous subgroups of observations with distinctive charac-
teristics. For example, the set of observations which satisfy
both "I(C017328_ > -0.64) = 0 and I(C029061_ > 4.63) =
0" includes 21 (out of the 48) stroke patients and none of
the controls. Clearly, this subgroup has a distribution of
positive and negative cases which is significantly different
than that of the original population. Due to the fact that
this set includes a large proportion of stroke patients, and
a very low proportion (in this case 0%) of the controls, we
shall say the requirement of "I(C017328_ > -0.64) = 0 and
I(C029061_ > 4.63) = 0" defines a "positive combinatorial
pattern." For simplicity, we will refer to this simply as a
positive pattern. A positive pattern can be interpreted as a
cluster of stroke patients defined by some limitation
imposed on the intensity of a few (in this case, two) peaks.
Moreover, if a new observation (i.e. one not appearing in
the given dataset) satisfies the limitations imposed by the
definition of this positive pattern, we shall conclude that
in all likelihood this observation is a stroke patient. In
what follows, if an observation satisfies the definition of a
pattern, we shall say that the observation is covered by
that pattern.
Similarly, let us consider now the set of observations sat-
isfying the limiting conditions "I(C06858_3 > 2.44) = 0
and I(C014069_ > 0.97) = 1." This set includes 11 (out of
32) controls and 1 (out of 48) stroke patient. We shall say
that these two conditions define a "negative combinato-
rial pattern," or simply a negative pattern.
We define below six important characteristics of a positive
or negative pattern:
1. Degree, defined as the number of variables involved in
the definition of the pattern;
Table 2: Peptides in support-set and their corresponding source
Training data Validation data
Peak ID (M/Z) Source Peak ID (M/Z) Source
C08689_4 (8689 Da) CM10 chip, Fraction 4, Low noalign Ce3 C08706_6 (8706 Da) CM10 chip, Fraction 4, Low noalign Ce3
C043564_ (43564 Da) IMAC chip, Fraction 6, High noalign Ce3 C043560_ (43560 Da) IMAC chip, Fraction 6, High noalign Ce3
C044761_ (44761 Da) IMAC chip, Fraction 6, High noalign Ce3 C044684_ (44684 Da) IMAC chip, Fraction 6, High noalign Ce3BMC Medical Informatics and Decision Making 2008, 8:30 http://www.biomedcentral.com/1472-6947/8/30
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SELDI peaks for the three potential biomarkers are shown in training and validation sets Figure 2
SELDI peaks for the three potential biomarkers are shown in training and validation sets. 8 spectra from each 
dataset were selected randomly to show that peaks in the training set are indeed the same peaks observed in validation set, 
even though the M/Z value is not identical in both datasets (possibly due to calibration error).BMC Medical Informatics and Decision Making 2008, 8:30 http://www.biomedcentral.com/1472-6947/8/30
Page 7 of 13
(page number not for citation purposes)
2. Positive prevalence, defined as the proportion of posi-
tive observations covered by the pattern;
3. Negative prevalence, defined as the proportion of neg-
ative observations covered by the pattern;
4. Positive homogeneity, defined as the proportion of
positive observations among all those observations cov-
ered by the pattern;
5. Negative homogeneity, defined as the proportion of
negative observations among all those observations cov-
ered the pattern;
6. Hazard ratio, defined as the ratio between the propor-
tion of positive observations among all those observa-
tions covered by the pattern, and the proportion of
positive observations among those observations not cov-
ered by the pattern.
The positive pattern described above (I(C017328_ > -
0.64) = 0 and I(C029061_ > 4.63) = 0) is defined by 2 pep-
tides and thus it is a degree 2 pattern. The set of observa-
tions covered by this pattern includes 21 stroke patients
and 0 controls. Thus, the positive prevalence of this pat-
tern is 43.75% (21 out of 48 stroke patients), and the neg-
ative prevalence is 0% (0 out of 32 controls). The positive
homogeneity of this positive pattern is 100%, since it cov-
ers only positive observations and its negative homogene-
ity is 0%. The hazard ratio of this pattern is (21/21)/(27/
59) = 2.19.
2.5. Classification model
We constructed an LAD model using the variables selected
in the support-set, with the purpose of classifying new
observations. An LAD model is simply a collection of pos-
itive and negative patterns of good characteristics, with
the property that every observation in the dataset is cov-
ered by at least one of the patterns. Ideally, the positive
patterns of a model would cover exclusively positive
observations, while its negative patterns would cover only
negative observations. In real-life applications, however,
one can rarely expect to be able to construct such a model.
We use a set-covering model (standard combinatorial
model) to select the patterns (rules) in the classification
model.
The LAD model in Table 3 consists of 3 positive and 2 neg-
ative patterns built using the intensity levels of the 3 pep-
tides in the support-set shown in Table 2. It can be seen
that:
￿ Each pattern has at most degree two (i.e. its defini-
tion involves at most two peaks);
￿ In average each positive pattern covers 72% of the
patients, and each negative pattern covers 50% of the
controls; clearly, each pattern defines a reasonably
large subset of patients or controls.
2.6. Data cleaning
During the LAD data analysis, two observations
(Stroke#61 and Stroke#23) were identified as potential
outliers in the dataset. We consider a patient (control) to
be an outlier if its measurements are very similar to those
of observations in the set of controls (patients). The rea-
son for such an assumption was that both observations
were consistently misclassified in preliminary cross-vali-
dation experiments. In the presence of the outliers the per-
formance of the LAD classification model drops by
approximately 2% in all three measures (accuracy, sensi-
tivity and specificity).
The discovery of these two outliers is a by-product of the
cross-validation evaluation of our LAD models. This "by-
product" feature is not necessarily inherent to the LAD
methodology, but was identified during our LAD experi-
ments. The two samples that were consistently misclassi-
fied by our LAD classifiers turned out to be abnormal
samples even though the cross-validation LAD experi-
ments were carried out without any prior suspicions.
Upon consulting the original database we confirmed that
Stroke#61, a stroke patient in the dataset, was in fact an
intra-cerebral haemorrhage (ICH) patient as opposed to
an ischemic stroke patient. This sample was mistakenly
added to the sample set by one of our collaborators unin-
tentionally. It was discovered through this data cleaning
process without prior knowledge. Stroke#23, appearing as
Table 3: LAD classification model
Patter
n
Degree Positive 
Prevalence
Negative 
Prevalence
Positive 
Homogeneity
Negative 
Homogeneity
Hazard Ratio C08689_
4
C043564
_
C044761
_
P1 1 37 (78.72%) 3 (9.68%) 92.50% 7.50% 3.52 ≤ -0.154
P2 2 35 (74.47%) 4 (12.90%) 89.74% 10.26% 2.92 ≤ 0.162 ≤ 0.553
P3 1 31 (65.96%) 2 (6.45%) 93.94% 6.06% 2.64 ≤ -0.237
N1 2 3 (6.38%) 20 (64.52%) 13.04% 86.96% 0.16 > 0.162 > -0.154
N2 1 2 (4.26%) 11 (35.48%) 15.38% 84.62% 0.22 > 0.728BMC Medical Informatics and Decision Making 2008, 8:30 http://www.biomedcentral.com/1472-6947/8/30
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a control in the dataset, was in fact a 63-year old Cauca-
sian female, with stroke risk factors of hypertension, prior
smoking, prior hormone replacement therapy and hyper-
cholesterolemia. She also has a history of migraine,
depression and asthma as a child. Even though, stroke#23
meets the criterion of being a control as defined in the
protocol (see previous section of 2.1 Description of sam-
ples and datasets), we decided to remove both Stroke#61
and Stroke#23 from the dataset with the following justifi-
cations: (1) We considered our data cleaning process as a
statistical outlier filter. Both Stroke#61 and Stroke#23 met
the criteria as outliers; (2) The fact that we were able to
discover a mistaken sample offered us confidence that the
outlier filter was valid to a large extent. We believed it is
reasonable to eliminate these two subjects from the data-
set. All further analysis was based on the remaining train-
ing set of 47 stroke patients and 31 controls.
2.7. Evaluation of the LAD classification model
The LAD model can be used for diagnosing "new" obser-
vations, i.e. observations not included in the original
dataset. If the observation satisfies h of the p positive pat-
terns in the model, and k of the n negative patterns, then
we define the "LAD discriminant function" as the expres-
sion h/p - k/n. The observation is classified based on the
sign of the discriminant function. If h/p - k/n is equal to 0,
the observation remains "unclassified". The LAD discrimi-
nant function corresponding to the training data and the
LAD classification model in Table 3 is plotted in Figure 3.
The region colored pink corresponds to the region where
the discriminant function is evaluated to have positive
sign, and hence an observation in this region will be clas-
sified as positive, while the blue region corresponds to the
negative sign and hence it will classify observations as
negative. Observations which lie on the surface of the dis-
criminant function will be left unclassified.
According to the above definition, the sensitivity of a
model is defined as the proportion of correctly classified
stroke patients, while the specificity of a model is defined
as the proportion of correctly classified controls. The accu-
racy of a model is defined as the average of its so-called
"corrected sensitivity" and "corrected specificity", where
the corrected sensitivity of a model is the usual sensitivity
plus half of the proportion of unclassified stroke patients,
and the corrected specificity of a model is the usual specif-
icity plus half of the proportion of unclassified controls.
Let P, N be the number of positive, respectively negative
observations. Let p, n denote the number of correctly clas-
sified positive, respectively negative observations. Let up,
un be the number of unclassified positive and negative
observations respectively. The formula for sensitivity, spe-
cificity, corrected sensitivity, corrected specificity, and
accuracy are presented below:
Sensitivity = p/P
Specificity = n/N
Corrected sensitivity = p/P + 1/2(up/P)
Corrected specificity = n/N + 1/2(un/N)
Accuracy = 1/2(Corrected sensitivity + Corrected specificity)
The accuracy, sensitivity, specificity and hazard ratio of
the diagnostic LAD system applied to the stroke data are
shown in the Table 4. We present the results of testing the
model on the training set, then on the validation set, and
finally the average results (with 95% confidence interval)
over ten random 10-folding cross-validation experiments
on the training set, where in each fold a model is built on
a part of the training set and tested on the remainder.
We have also computed the accuracy of other frequently
used classification methods (C4.5 decision trees, Logistic
regression, Support vector machines, and Multilayer per-
ceptron) available in the Weka software package for the
purpose of assessing the relative quality of our results. The
control parameters of each of the other classification
methods utilized were extensively calibrated to obtain the
best performance (average accuracy in cross-validation
experiments). These results are listed in Table 5. From
Tables 4 and 5 we observe that the LAD model has signif-
icantly better performance on the independent validation
set compared to the other classification models.
To visualize the quality of the model on the observations
in the training and test dataset we present Figures 4. These
plots are visualizations of the coverage of observations by
patterns in the model. The rows represent the observa-
tions with the positive observations above the horizontal
dashed line, while the negative observations lie below the
dashed line. The columns represent the pattern (first pos-
itive patterns followed by negative patterns). If an obser-
vation is covered by a positive pattern, then the
corresponding pixel is coloured red, while if it is covered
by a negative pattern it is coloured blue. From the two
plots we can observe that the positive observations are
covered by a majority of positive patterns, while the nega-
tive ones are covered by a majority of negative patterns.
This is an indication of the high quality of the LAD model.
2.8. LAD-based severity score
To further evaluate our choice of a support-set, we
attempted to build a model to predict the severity of
stroke. When the patients were admitted to the hospital
after a stroke, the stroke severity was evaluated by the phy-
sician using the National Institutes of Health Stroke Scale
(NIHSS). NIHSS is used to measure the severity of neuro-BMC Medical Informatics and Decision Making 2008, 8:30 http://www.biomedcentral.com/1472-6947/8/30
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logical dysfunction at the time of a stroke [15]. A score
greater than 25 indicates very severe neurological impair-
ment; a score between 15 and 25 indicates severe impair-
ment, while a score between 5 and 15 indicates mild to
moderately severe impairment, and a score less than 5
indicates mild impairment.
We have identified a formula which can reasonably pre-
dict the severity score based on the knowledge of the 3
peaks (C08689_4, C043564_, and C044761_) on which
the stroke diagnostic system was built. We have also
experimented with several types of regression methods
(Linear Regression, Multilayer Perceptron, Support Vector
Regression, and LAD Regression). The results are summa-
rized in Table 6, where the Pearson correlation column
refers to the correlation between the predicted and the
originally given severity scores, and the root mean square
error (RMSE) is that of the predicted scores compared
again with the originally given ones. Obviously, the ideal
correlation is 1, and the ideal root mean square error is 0.
It appears that both RMSE and the correlation show that
the chosen support-set can provide (at least a partial)
explanation of the level of the stroke severity score. LAD
regression seems to provide the best results among the
four methods. The stroke severity prediction of the LAD
model for a patient c is given by the formula
R(c) = 8.61 - 4.63 * Q1 - 9.29 * Q2 - 4.69 * Q3 - 7.61 * Q4
- 6.09 * Q5 -6.11 * Q6 - 6.48 * Q7 + 8.95 * Q8 + 9.13 *
Q9 + 5.90 * Q10 + 3.34 * Q11
where the values of Q1,...,Q11 are either 0 or 1 and are
given by the formulas in Table 7.
For illustration, consider the case of stroke patient
Stroke#80 having the following measurements:
Table 4: Performance of LAD model
Performance Training set Validation set Cross-validation
Logical Analysis of Data Model Accuracy 82.6% 74.8% 79.8 ± 2.9%
Sensitivity 89.4% 77.5% 85.4 ± 5.4%
Specificity 74.2% 72.0% 70.6 ± 3.2%
Hazard Ratio 8.1 3.2 3.0 ± 0.3
A 3-D plot of the discriminant function on the training data Figure 3
A 3-D plot of the discriminant function on the training data. The region colored pink (blue) represents the positively 
(negatively) classified region. The surface of the discriminant function is colored purple.BMC Medical Informatics and Decision Making 2008, 8:30 http://www.biomedcentral.com/1472-6947/8/30
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C08689_4 = -1.098, C043564_ = 1.547 and C044761_ =
3.112. For this patient Q1 = 0, Q2 = 0, Q3 = 0, Q4 = 0, Q5
= 0, Q6 = 0, Q7 = 1, Q8 = 1, Q9 = 0, Q10 = 0, and Q11 =
0. Therefore, R(Stroke#80) = 8.61 - 6.48 + 8.95 = 11.08.
The original severity score of Stroke#80 was 12.
2.9. Classification and regression software
The LAD results described in this study were obtained
with the use of "Ladoscope" [16], a publicly available
implementation of LAD, written and maintained by Pierre
Lemaire. Each of the steps involved in the construction of
a LAD classifier (discretization, feature selection, pattern
generation, model selection, and classification), as
described in this study, are available in Ladoscope. The
remaining classification methods (Support vector
machines, C4.5 decision trees, Logistic regression and
Multilayer perceptron) as well as the regression methods
(Support vector regression, linear regression) utilized for
comparison are available in the Weka package [17]. The
LAD regression algorithm used for developing the LAD-
based severity score formula was implemented by the
authors and a public version of it is currently being pre-
pared.
Discussion
The main emphasis of this study has been to identify a
small subset of variables that could allow the develop-
ment of accurate and simple models for predicting stroke.
The basic assumption being that a simple model would
provide an easy and intelligible tool for medical experts to
identify the stroke status of the patients by applying a
small number of simple tests, such as drawing some
blood, and performing the tests necessary to measure the
levels of a few biomarkers.
On the value of predicting stroke or the intensity of the
stroke using these models, it is conceivable that patients
with acute stroke syndromes and cardiovascular instabil-
ity (i.e. shock, arrhythmias) may have acute phase protein
release including inflammatory mediators that may con-
found the protein expression pattern observed in the cur-
rent study cohort.
We have described a detailed pre-processing algorithm for
retaining important peaks. While the pre-processing pro-
cedure utilized was somewhat involved, it utilized a series
of steps that in principle are not biased towards any of the
classification methods applied to the problem: 1) removal
of peaks with weak spectrum quality and peaks that were
not reproducible across experiments, or did not have a sig-
nificant individual predictive power; 2) removal of varia-
bles that did not show a good predictive power when
utilized in pairs with other variables. The support-set of 3
peaks was chosen to improve the accuracy of classification
in cross-validation experiments. In our early experiments,
all classification methods (including LAD) overfit the
training data when the support-set consisted of a large
numbers of variables. While it is conceivable that a careful
selection of variables would benefit other algorithms and
deteriorate LAD performance, we did not experience this
in our experiments. We notice here that the support-set
selection procedure utilized was somewhat biased to the
way in which the LAD and C4.5 classification algorithms
work. While this choice may favor these two algorithms,
we have observed a consistent increase in accuracy over all
algorithms when utilizing the 3-peak support set. Moreo-
ver, we believe that a detailed evaluation of algorithms for
feature selection is beyond the scope of the present study.
The strengths of the classification model proposed in this
study are: a) small sized support-set, b) small number of
Table 5: Performance of other classification methods:
Method Performance Training Validation Cross validation
C4.5 Decision Trees Accuracy 84.5% 69.3% 75.9 ± 2.9%
Sensitivity 90.3% 76.0% 80.4 ± 4.8%
Specificity 78.7% 62.5% 71.4 ± 3.5%
Logistic Regression Accuracy 73.8% 64.8% 71.1 ± 1.8%
Sensitivity 64.5% 52.0% 59.4 ± 2.7%
Specificity 83.0% 77.5% 82.8 ± 3.3%
Support Vector Machines Accuracy 81.8% 68.5% 77.6 ± 3.1%
Sensitivity 74.2% 52.0% 87.50 ± 3.3%
Specificity 89.4% 85.0% 67.80 ± 5.2%
Multilayer Perceptron Accuracy 88.8% 68.5% 82.20 ± 2.4%
Sensitivity 96.8% 72.0% 78.00 ± 3.5%
Specificity 80.9% 65.0% 86.40 ± 3.7%BMC Medical Informatics and Decision Making 2008, 8:30 http://www.biomedcentral.com/1472-6947/8/30
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patterns, c) interpretability and d) high accuracy on vali-
dation. The three peaks in the support-set identified,
along with the patterns produced, can be seen as biomar-
kers, and their performance in predicting stroke qualifies
them as research hypotheses for biologists and stroke spe-
cialists. This study demonstrates the potential of such a
technique to help understand better the proteomic mech-
anisms behind stroke and its causes.
In addition to a classification model, we have been able to
provide a predictive model to predict the intensity of a
stroke, as defined by the NIH Stroke Scale. The scoring
function built with LAD uses 11 rules constructed on the
basis of the same 3 peptides in the support-set used for
deriving the classification model of Table 2. This is an
interesting fact in itself, since the original NIH Stroke
Scale is constructed on the basis of clinical measurements
and on subjective evaluation by medical doctors. The der-
ivation of such a simple function that provides a good
approximation to the standard NIHSS suggests the poten-
tial of this technique towards the construction of an auto-
matic index that could provide valuable information
regarding the severity of the stroke. Clearly, the use of
more peaks could potentially improve the correlation and
mean squared error on the training set, but this would
most likely produce inferior results on validation, due to
the small size of the training set. A rule of thumb for
regression experiments is to have at least 8 to 10 times as
many observation points as predictor variables. Since each
rule can be regarded as an individual (combinatorial) pre-
dictor – taking values 0 or 1 at a given observation
depending on whether the rule is satisfied or not on that
observation – the set of 11 rules generated was just about
enough to comply with this general requirement. Indeed,
the predictive model was observed to provide a reasona-
bly accurate prediction for the validation dataset, in spite
of the limited training data.
In this study, LAD has been applied on a small sized data-
set. In general, LAD can be scaled very well to large data-
sets. It has been successfully applied to studies with a large
number of patients [11]. The combinatorial nature of LAD
renders it sensitive to a large number of variables, just as
other algorithms, such as decision trees. In such cases, fea-
ture selection has simplified the LAD computations and
showed that a significantly small support-set is usually
enough to construct LAD models of superior perform-
ance. A detailed description of different pattern genera-
tion algorithms along with the complexity is presented in
[18-21].
Conclusion
We successfully identified 3 biomarkers that can detect
ischemic stroke with an accuracy of 75%. Table 3 shows
that the performance of the classification model on the
validation set and on cross-validation does not deteriorate
significantly when compared to that on the training set.
This is more evident when we compare with the decrease
in accuracy observed in the LAD experiments with the
experiments using other classification algorithms, shown
in Table 4. This illustrates the robustness of our results.
As in the case of the LAD classification model, the regres-
sion results presented in Table 5 validates the function
Visualization of the pattern coverage on the training data  (left) and test data (right) Figure 4
Visualization of the pattern coverage on the training 
data (left) and test data (right). Each row indicates an 
observation, and each column indicates a pattern. All obser-
vations above the dashed line are stroke patients, while those 
below the dashed line are controls. A cell corresponding to 
an observation j and positive (negative) pattern p is colored 
red (blue) if j is covered by pattern p.
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constructed on our support-set for approximating the
severity scores of stroke patients. The correlation and root
mean absolute error of the LAD regression are consistently
superior to those of the other algorithms used. The
decrease in correlation from training set to validation set
is smaller than that observed in the results of the other
algorithms.
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